Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eflornithine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 0.92 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | ARG1 | P05089 | 3/20 | 0.59 |
| ▸ | ARG2 | P78540 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflornithine SCHEMBL4510 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL3238104 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL559145 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL5051665 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL1397750 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL7208883 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL6779168 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL6779172 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL3244711 | 0.98 | ODC1 (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL1322403 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368029-B1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | USWM LLC (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137642-A1 | METHODS OF TREATING PATIENTS HAVING TYPE 1 DIABETES WITH EFLORNITHINE | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| EP-3523274-B1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | ORBUS THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | claimed |
| US-12350246-B2 | Eflornithine and sulindac, fixed dose combination formulation | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2025-07-08 | — | — | US | claimed |
| US-20250186380-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | Cancer Prevention Pharmaceuticals (US) | 2025-06-12 | — | — | US | claimed |
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | ORBUS THERAPEUTICS INC (US) | 2025-02-06 | — | — | US | claimed |
| US-20240173284-A1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | US | claimed |
| US-20240165063-A1 | METHODS FOR TREATING NEUROBLASTOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-23 | — | — | US | claimed |
| US-20240148647-A1 | AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH | NAVIN SAXENA RESEARCH & TECHNOLOGY PRIVATE LIMITED (IN) | 2024-05-09 | — | — | US | claimed |
| US-11925613-B2 | Eflornithine and sulindac, fixed dose combination formulation | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | claimed |
| US-20220040130-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | CANCER PREVENTION PHARMACEUTICALS, INC. | 2022-02-10 | — | — | US | claimed |
| US-20210378999-A1 | METHODS FOR TREATING NEUROBLASTOMA | USWM, LLC | 2021-12-09 | — | — | US | claimed |
| WO-2021191928-A1 | EFLORNITHINE COMPOSITION AND DOSAGE FORMS FOR THE TREATMENT OF VIRAL INFECTION | NAVIN SAXENA RESEARCH & TECHNOLOGY PVT. LTD. (IN) | 2021-09-30 | — | — | WO | claimed |
| US-10973790-B2 | Eflornithine and sulindac, fixed dose combination formulation | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | claimed |
| US-10945981-B2 | Methods for treating familial adenomatous polyposis | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | claimed |
| US-20210038549-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Orbus Therapeutics, Inc. | 2021-02-11 | — | — | US | claimed |
| WO-2020236562-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | WO | claimed |
| US-20200360329-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | USWM, LLC | 2020-11-19 | — | — | US | claimed |
| US-10786470-B2 | Formulations for administration of eflornithine | Orbus Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | claimed |
| CN-108366982-A | Eflornithine and sulindac, the combination preparation of fixed dosage | 癌症预防制药股份有限公司 | 2018-08-03 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137642-A1 | METHODS OF TREATING PATIENTS HAVING TYPE 1 DIABETES WITH EFLORNITHINE | IAPP, GLP1R, IRS1 | ODC1 702/4885BLM 4850/4885LMNA 1467/4885 |
| US-10786470-B2 | Formulations for administration of eflornithine | EFNA1, IDH1, ABCC5 | ODC1 441/4885BLM 4575/4885LMNA 1255/4885 |
| US-20240148647-A1 | AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH | EFNA1, CYP8B1, CYP2C18 | ODC1 605/4885BLM 4866/4885LMNA 1128/4885 |
| US-20210038549-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | EFNA1, KMT5A, ETV1 | ODC1 403/4885BLM 4428/4885LMNA 1278/4885 |
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, SHMT1 | ODC1 19/4885BLM 3894/4885LMNA 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.